ASCO 2023: Abemaciclib Safe and Effective in Patients 65 Years and Older With High-Risk Early Breast Cancer
Researchers say dose reductions should be considered with adverse events
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.